Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The constitutive proteasome is a major intracellular multi-subunit protease complex responsible for the degradation of misfolded, damaged, and short-lived regulatory proteins via the ubiquitin-proteasome system. It is ubiquitously expressed in almost all eukaryotic cells and consists of a 20S catalytic core particle capped by 19S regulatory particles to form the active 26S proteasome. The catalytic core contains three active subunits—β1 (caspase-like), β2 (trypsin-like), and β5 (chymotryptic-like)—which mediate protein cleavage. In contrast to the immunoproteasome, which is induced during inflammation and expressed in immune cells, the constitutive proteasome maintains baseline cellular proteostasis.
Dysregulation of the constitutive proteasome is heavily implicated in various diseases, particularly hematological malignancies like multiple myeloma and mantle cell lymphoma, where cancer cells rely on high proteasomal activity to survive proteotoxic stress. It is also linked to neurodegenerative diseases, where its function declines, leading to toxic protein aggregation. Clinically, the constitutive proteasome is a highly validated therapeutic target. FDA-approved proteasome inhibitors, such as bortezomib, carfilzomib, and ixazomib, primarily target the β5 chymotryptic subunit, inducing severe endoplasmic reticulum stress, unfolded protein response, and apoptosis in cancer cells. However, systemic inhibition of this ubiquitous complex is associated with significant toxicities, such as peripheral neuropathy and myelosuppression, prompting the development of more selective inhibitors.
Inhibition of the chymotrypsin-like activity of the beta5 subunit of the 20S core particle, leading to accumulation of ubiquitinated proteins, endoplasmic reticulum stress, and apoptosis.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Constitutive proteasome (cCP).